QCM Cayman’s Immunogen Inc IMGN Stock Holding History

QCM Cayman’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-22,269	Closed	-$170K	–	217
2017 Q3	$170K	Buy	+22,269	New	+$148K	0.44%	116

Other funds holding IMGN

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QCM Cayman's IMGN Position: Q4 2017 in Review

QCM Cayman sold out of Immunogen Inc (IMGN) in Q4 2017, closing a stake of 22,269 shares — an estimated $170K sold.

QCM Cayman first reported a position in IMGN in Q3 2017 and held it in 1 quarter. The position peaked at $170K in Q3 2017. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2017.

QCM Cayman reported no remaining Immunogen Inc position as of Q4 2017 after selling out during the quarter.
QCM Cayman sold 22,269 Immunogen Inc shares in Q4 2017, an estimated $170K.
QCM Cayman first reported a position in Immunogen Inc in Q3 2017 and held it in 1 quarter.
QCM Cayman's Immunogen Inc position peaked at $170K in Q3 2017.
200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2017.

Based on QCM Cayman's 13F filing for Q4 2017, filed 14 Feb 2018.